Clinical Trials Logo

Bullous Pemphigoid clinical trials

View clinical trials related to Bullous Pemphigoid.

Filter by:

NCT ID: NCT02360202 Recruiting - Bullous Pemphigoid Clinical Trials

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid

RECOPB
Start date: April 2015
Phase: Phase 4
Study type: Interventional

Clinical observation frequently shows a paradoxical effect of topical corticosteroids in charge of a sudden melting of edema in the first days of treatment, which could be due to mobilization of extracellular. No study has shown the value of this measure in patients treated with topical steroids. This uncertainty, coupled with the observation of the paradoxical effects of topical steroids on edema are some patients that despite the systemic absorption of clobetasol propionate, a salt-free diet is not currently recommended practice.

NCT ID: NCT00802243 Recruiting - Bullous Pemphigoid Clinical Trials

Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid

ARABUL
Start date: September 2007
Phase: Phase 2
Study type: Interventional

Bullous pemphigoid (BP) is the most common blistering auto-immune disease of skin with an incidence estimated to 400 new cases per year. Topical corticosteroid therapy is considered the standard treatment for bullous pemphigoïd in 2002. Topical corticosteroid requires an initial large hospitalization during the acute phase and rehospitalization during relapse. The usefulness of immunosuppressive drugs have suggested by uncontrolled study. In this way, leflunomide could be an alternative therapy, and to reduce relapse and/or resistance risks. This study could prove the efficacity of leflunomide, associated with short time topical corticosteroids.